Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes how he helps his EGFR lung cancer patients make decisions about next steps in treatment when their cancers grow.

[powerpress]

Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.

[powerpress]

Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung cancer growth.

[powerpress]

How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.

[powerpress]

What should lung cancer patients know about their disease? Dr. Jonathan Riess argues that patients should understand what type of lung cancer they have and which, if any, mutations their lung tumors may have. He explains why in this video.

[powerpress]

If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal of Stanford University Medical Center discusses the reasons for and against it. February 2014.

[powerpress]

Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center talks about the next generation EGFR inhibitors that may soon become available. February 2014.

[powerpress]

Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute discusses whether or not patients on targeted therapies, such as EGFR inhibitors, should stay on those therapies after their cancers begin to grow again. February 2014.

[powerpress]

Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

[powerpress]

Dr. Charles Rudin of Memorial Sloan Kettering talks about RAF and other genetic mutations that play a role in the growth of lung cancer. February 2014.

[powerpress]